$0.32
-0.03 (-7.96%)
Open$0.34
Previous Close$0.34
Day High$0.34
Day Low$0.31
52W High$3.85
52W Low$0.26
Volume—
Avg Volume2.19M
Market Cap13.85M
P/E Ratio—
EPS$-10.78
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+7,773.9% upside
Current
$0.32
$0.32
Target
$24.85
$24.85
$15.48
$24.85 avg
$31.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.16M | 3.54M |
| Net Income | -163,651 | -194,157 | -147,578 |
| Profit Margin | -3.9% | -4.7% | -4.2% |
| EBITDA | -229,901 | -240,916 | -206,498 |
| Free Cash Flow | -133,630 | -165,029 | -157,801 |
| Rev Growth | +8.4% | +2.1% | +5.7% |
| Debt/Equity | 0.23 | 0.22 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |